前列腺癌双极雄激素治疗的研究进展

尤祥云; 孙德明; 喻俊峰; 易成; 向振东

doi:10.13201/j.issn.1001-1420.2021.12.015

前列腺癌双极雄激素治疗的研究进展

- 三峡大学人民医院宜昌市第一人民医院泌尿外科(湖北宜昌, 443000)
基金项目:
湖北省自然科学基金面上类项目（No：2020CFB379）；三峡大学学位论文培优基金项目（No：2020SSPY108）；宜昌市财政科技专项基金（No：A20-2-021）

详细信息

通讯作者: 向振东,E-mail:druid456@msn.com

中图分类号: R737.25

收稿日期: 2020-09-28

Advances in the treatment of prostate cancer with bipolar androgen therapy

- Department of Urology, People's Hospital of China Three Gorges University, First People's Hospital of Yichang, Yichang, Hubei, 443000, China

More Information

Corresponding author: XIANG Zhendong, E-mail: druid456@msn.com

Received Date: 28 September 2020

摘要

摘要: 双极雄激素治疗（bipolar androgen therapy，BAT）是去势抵抗性前列腺癌（castration resistant prostate cancer，CRPC）的新疗法，可显著降低部分患者血清前列腺癌特异性抗原（prostate specific antigen，PSA）水平、提高患者生活质量和恢复去势治疗的敏感性，在CRPC患者的治疗中展现了巨大潜力，本文对BAT在前列腺癌中的相关研究进展作一综述。
- 双极雄激素治疗 /
- 去势抵抗性前列腺癌 /
- 前列腺癌特异性抗原 /
- 雄激素受体
Abstract: Bipolar androgen therapy(BAT) is a novel treatment for castration resistant prostate cancer(CRPC), which can significantly reduce the level of prostate specific antigen in serum and improve the quality of life for patients. Now, there are significant advantages in the treatment of CRPC with BAT, so this article reviews the progress of clinical researchs of BAT in prostate cancer.
- bipolar androgen therapy /
- castration resistant prostate cancer /
- prostate specific antigen /
- androgen receptor

HTML全文

参考文献(31)

[1]	Fitzmaurice C, Akinyemiju TF, Al Lami FH, et alet al.Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016:A Systematic Analysis for the Global Burden of Disease Study[J].JAMA Oncol, 2018, 4(11):1553-1568.
[2]	Feng RM, Zong YN, Cao SM, et al.Current cancer situation in China:good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun(Lond), 2019, 39(1):22.
[3]	刘成成, 石春雷, 石菊芳, 等.2015-2017年中国城市居民肿瘤预防意识健康素养及相关因素分析[J].中华预防医学杂志, 2020, 68(1):47-53.
[4]	El-Amm J, Aragon-Ching JB.The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer[J].Clin Med Insights Oncol, 2019, 13:1179554919833927.
[5]	Xie T, Song XL, Wang C, et al.The role of androgen therapy in prostate cancer:from testosterone replacement therapy to bipolar androgen therapy[J].Drug Discov Today, 2021, 26(5):1293-1301.
[6]	Evans CP.Bipolar androgen therapy:an intriguing paradox[J].Lancet Oncol, 2018, 19(1):8-10.
[7]	Liu RJ, Hu Q, Li SY, et al.The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer:Systematic Review and Meta-Analysis[J].Technol Cancer Res Treat, 2021, 20:15330338211035260.
[8]	Schiewer MJ, Knudsen KE.DNA Damage Response in Prostate Cancer[J].Cold Spring Harb Perspect Med, 2019, 9(1):a030486.
[9]	Chatterjee P, Schweizer MT, Lucas JM, et al.Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage[J].J Clin Invest, 2019, 130:4245-4260.
[10]	Kokal M, Mirzakhani K, Pungsrinont T, et al.Mechanisms of Androgen Receptor Agonist-and Antagonist-Mediated Cellular Senescence in Prostate Cancer[J].Cancers(Basel), 2020, 12(7):1833.
[11]	Lam HM, Nguyen HM, Labrecque MP, et al.Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts[J].Eur Urol, 2020, 77(2):144-155.
[12]	Intasqui P, Bertolla RP, Sadi MV.Prostate cancer proteomics:clinically useful protein biomarkers and future perspectives[J].Expert Rev Proteomics, 2018, 15(1):65-79.
[13]	Batra A, Winquist E.Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer[J].Expert Opin Emerg Drugs, 2018, 23(4):271-282.
[14]	Icard P, Fournel L, Wu Z, et al.Interconnection between Metabolism and Cell Cycle in Cancer[J].Trends Biochem Sci, 2019, 44(6):490-501.
[15]	Burkhart DL, Morel KL, Sheahan AV, et al.The Role of RB in Prostate Cancer Progression[J].Adv Exp Med Biol, 2019, 1210:301-318.
[16]	Gravina GL, Marampon F, Sanita P, et al.Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR(ser81) and CDK1 signaling:biological implications for men treated with testosterone replacement therapy[J].Oncotarget, 2017, 8(69):113792-113806.
[17]	Leone G, Buttigliero C, Pisano C, et al.Bipolar androgen therapy in prostate cancer:Current evidences and future perspectives[J].Crit Rev Oncol Hematol, 2020, 152:102994.
[18]	Sugiura M, Sato H, Kanesaka M, et al.Epigenetic modifications in prostate cancer[J].Int J Urol, 2021, 28(2):140-149.
[19]	Joly-Pharaboz MO, Ruffion A, Roch A, et al.Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line[J].J Steroid Biochem Mol Biol, 2000, 73(5):237-249.
[20]	Kim JH, Lee H, Shin EA, et al.Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression[J].Expert Opin Ther Targets, 2017, 21(9):911-920.
[21]	Etheridge T, Damodaran S, Schultz A, et al.Combination therapy with androgen deprivation for hormone sensitive prostate cancer:A new frontier[J].Asian J Urol, 2019, 6(1):57-64.
[22]	Thomas L, Baratchian M, Sharifi N.Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer[J].Eur Urol, 2020, 77(2):156-157.
[23]	Schweizer MT, Antonarakis ES, Wang H, et al.Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer:results from a pilot clinical study[J].Sci Transl Med, 2015, 7(269):269ra2.
[24]	Bluemn EG, Coleman IM, Lucas JM, et al.Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling[J].Cancer Cell, 2017, 32(4):474-489 e6.
[25]	Schweizer MT, Wang H, Luber B, et al.Bipolar Androgen Therapy for Men With Androgen Ablation Naive Prostate Cancer:Results From the Phase ⅡBATMAN Study[J].Prostate, 2016, 76(13):1218-1226.
[26]	Teply BA, Wang H, Luber B, et al.Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide:an open-label, phase 2, multicohort study[J].Lancet Oncol, 2018, 19(1):76-86.
[27]	Markowski MC, Shenderov E, Eisenberger MA, et al.Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer[J].Prostate, 2020, 80(5):407-411.
[28]	Markowski MC, Wang H, Sullivan R, et al.A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer(RESTORE):A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts[J].Eur Urol, 2021;79(5):692-699.
[29]	Markowski MC, Silberstein JL, Eshleman JR, et al.Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer[J].JCO Precis Oncol, 2017, 2017:PO.17.00127.
[30]	Denmeade SR, Wang H, Agarwal N, et al.TRANSFORMER:A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer[J].J Clin Oncol, 2021, 39(12):1371-1382.
[31]	Denmeade SR.Bipolar androgen therapy in the treatment of prostate cancer[J].Clin Adv Hematol Oncol, 2018, 16(6):408-411.